Previous close | 10.29 |
Open | 10.29 |
Bid | 10.75 x 400 |
Ask | 10.85 x 100 |
Day's range | 10.18 - 10.82 |
52-week range | 5.15 - 12.45 |
Volume | |
Avg. volume | 226,329 |
Market cap | 1.219B |
Beta (5Y monthly) | 1.40 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.42 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 14.17 |
The average of price targets set by Wall Street analysts indicates a potential upside of 48.9% in Centessa Pharmaceuticals (CNTA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024. “With all three of our core programs
Centessa Pharmaceuticals (CNTA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.